Roche’s US subsidiary Genentech breaks ground on $700 million manufacturing facility in North Carolina
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
The company is bringing precision therapies for gynaecological cancers
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
The company has improved access to quality healthcare for seniors across both urban and rural areas
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Subscribe To Our Newsletter & Stay Updated